Novel coronavirus 2019 (COVID-19) has emerged as a major international public health concern. While much of the morbidity and mortality associated with COVID-19 has been attributed to acute respiratory distress syndrome (ARDS) or end-organ failure, emerging data suggest that disorders of coagulation, in particular hypercoagulability and venous thromboembolism (VTE), may represent an additional major, and possibly preventable, complication (Wu C, et al. JAMA Intern Med. 2020 Mar 13. [Epub ahead of print] and Tang N, et al. Thromb. Haemost. 2020 Feb 19. [EPub Ahead of Print]). Abnormal coagulation testing results, especially markedly elevated D-dimer and FDP, have been associated with a poor prognosis in COVID-19 infection. We propose the following Electronic Health Record (EHR)-guided 10000-patient, retrospective observational cohort study to assess VTE incidence, risk factors, prevention and management patterns, and thrombotic outcomes in patients with COVID-19 infection. In order to gain the valuable perspective of other regional and national centers providing care for large populations of COVID-19, we have started a collaborative network with 5 additional sites which will provide us with de-identified data from 1000 patients each. These 5000 patients in addition to the 5000-patient cohort we are enrolling within the Mass General Brigham Network will comprise this study population.
Aim #1: To determine the 30-day and 90-day frequencies of adjudicated, symptomatic arterial
and venous thromboembolic events in patients with COVID-19 infection. Symptomatic VTE is
defined as symptomatic DVT or PE, confirmed by imaging, within 30 days of randomization.
Arterial thromboembolism will be comprised of myocardial infarction, stroke or systemic
embolism, acute limb ischemia.
Aim #2: To determine VTE-related risk factors, prevention and management patterns, and 30-day
and 90-day all-cause mortality, bleeding, and thrombotic outcomes in patients with COVID-19
infection. 30- and 90-day bleeding outcomes will include ISTH-major and clinically-relevant
nonmajor bleeding. Thrombotic outcomes will include symptomatic VTE, myocardial infarction,
stroke or systemic embolism, acute limb ischemia, and cardiovascular death.
Aim #3: To determine through multivariate logistic regression modeling, independent risk
factors for VTE in patients with COVID-19 infection that could be used to identify those who
may benefit from thromboprophylaxis during hospitalization and after discharge.
Study Design: 10000 patient U.S.-based EHR-guided, retrospective observational cohort
analysis. Data will abstracted through the EHR. Because this is a computer-generated
observational retrospective registry, informed consent will not be practical. Accordingly, we
will ask our Institutional Review Board to waive the requirement for informed consent.
Participating sites (University of Colorado, Jefferson Health, BIDMC, Anne Arundel Medical
Center, and another site to be named) will obtain IRB approval at their own institutions.
Study Population: Patients are eligible if they are ≥18 years of age and meet the following
criteria:
1. Positive COVID-19 PCR AND
2. Inpatient OR outpatient management of COVID-19 infection
Patient Enrollment: We will create a search engine query through the EHR to identify patients
with an objective COVID-19 diagnosis who are hospitalized or being treated as outpatients.
This will be executed retrospectively for patients already objectively-diagnosed at
participating clinical sites.
Primary Outcome: 30-day and 90-day frequency of objectively confirmed, adjudicated arterial
thromboembolism or VTE, including deep venous thrombosis (DVT) and pulmonary embolism (PE).
Secondary Outcome: 30-day and 90-day frequency of adjudicated all-cause death, bleeding, and
thromboembolic outcomes.
Additional Variables of Interest: Additional measured variables will include VTE-related risk
factors, prevention and management patterns, and cause of death. We will review the notes and
diagnostic testing sections of the Electronic Health Record to complete an electronic case
report form for each subject.
Follow-Up: Follow-up will consist of Electronic Health Record review at 30 days and 90 days
from study entry.
Other: No intervention
No intervention
1. Positive COVID-19 PCR AND
2. Inpatient OR outpatient management of COVID-19 infection
Brigham and Women's Hospital
Boston, Massachusetts, United States
Investigator: Gregory Piazza, MD, MS
Contact: 617-732-6984
gpiazza@partners.org
Gregory Piazza, MD, MS
617 732 6984
gpiazza@partners.org
Gregory Piazza, MD, MS, Principal Investigator
BWH